BCL2L1 and ovarian cancer: The downregulation of Bcl-xl could reverse cisplatin resistance in ovarian cancer cells, and induce cell death caused by cisplatin at a low concentration (80), and confers sensitivity to cisplatin-resistant mesothelioma cells (81).